The Innovative Medicines Initiative (IMI)
The EMTRAIN project is funded by the Innovative Medicines Initiative (IMI) Joint Undertaking, a large scale public-private partnership between the European Union and the pharmaceutical industry association EFPIA.
With its 2 billion euro research programme, IMI aims to speed up the development of better and safer medicines for patients, and to boost biopharmaceutical innovation in Europe. Through its unique and innovative funding scheme, IMI supports research projects in the areas of:
- knowledge management,
- education and training.
The research consortia participating in IMI projects include small- and medium-sized enterprises, patient organizations, academia and other research organizations, hospitals, public authorities and large pharmaceutical companies.
The European Commission's Seventh Framework Programme will contribute € 1 billion to the IMI research programme. That amount will be matched by in kind contributions worth at least another € 1 billion from the pharmaceutical companies that are member of EFPIA, the European Federation of Pharmaceutical Industries and Associations.
Education and Training
The IMI Education and Training pillar (E&T) has identified a number of gaps within education & training in support of the medicines development process. In order to address these gaps, a number of activities were proposed in 2008, including the establishment of a European Medicines Research Training Network and the development of training programmes in safety sciences, medicine development and pharmacovigilance. IMI E&T projects will therefore support the education and training of current and future professionals involved in biomedical R&D.
IMI Education & Training Projects in IMI's 1st Call
- European Medicines Research Training Network (EMTRAIN)
- Safety Sciences for Medicines Training Programme (SafeSciMET)
- Pharmaceutical Medicine Training Programme (PharmaTrain)
- Pharmacovigilance Training Programme (Eu2P)